HK1214169A1 - 用於治疗癌症的瑞戈非尼和乙酰水杨酸的组合 - Google Patents
用於治疗癌症的瑞戈非尼和乙酰水杨酸的组合 Download PDFInfo
- Publication number
- HK1214169A1 HK1214169A1 HK16102326.3A HK16102326A HK1214169A1 HK 1214169 A1 HK1214169 A1 HK 1214169A1 HK 16102326 A HK16102326 A HK 16102326A HK 1214169 A1 HK1214169 A1 HK 1214169A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- cancer
- combination
- regorafenib
- acetylsalicylic acid
- limited
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/60—Salicylic acid; Derivatives thereof
- A61K31/612—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid
- A61K31/616—Salicylic acid; Derivatives thereof having the hydroxy group in position 2 esterified, e.g. salicylsulfuric acid by carboxylic acids, e.g. acetylsalicylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12185852.6 | 2012-09-25 | ||
| EP12185852 | 2012-09-25 | ||
| PCT/EP2013/069735 WO2014048881A1 (en) | 2012-09-25 | 2013-09-23 | Combination of regorafenib and acetylsalicylic acid for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HK1214169A1 true HK1214169A1 (zh) | 2016-07-22 |
Family
ID=46963566
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HK16102326.3A HK1214169A1 (zh) | 2012-09-25 | 2013-09-23 | 用於治疗癌症的瑞戈非尼和乙酰水杨酸的组合 |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US10898500B2 (https=) |
| EP (1) | EP2900269B1 (https=) |
| JP (1) | JP6294888B2 (https=) |
| KR (1) | KR102210575B1 (https=) |
| CN (1) | CN104994876A (https=) |
| AU (1) | AU2013322854B2 (https=) |
| BR (1) | BR112015006686B1 (https=) |
| CA (1) | CA2885688C (https=) |
| CL (1) | CL2015000744A1 (https=) |
| CY (1) | CY1120939T1 (https=) |
| DK (1) | DK2900269T3 (https=) |
| EA (1) | EA032023B1 (https=) |
| ES (1) | ES2687985T3 (https=) |
| HK (1) | HK1214169A1 (https=) |
| HR (1) | HRP20181462T1 (https=) |
| HU (1) | HUE039878T2 (https=) |
| IL (1) | IL237690B (https=) |
| LT (1) | LT2900269T (https=) |
| MX (1) | MX357035B (https=) |
| MY (1) | MY183969A (https=) |
| NZ (1) | NZ705860A (https=) |
| PH (1) | PH12015500587A1 (https=) |
| PL (1) | PL2900269T3 (https=) |
| PT (1) | PT2900269T (https=) |
| RS (1) | RS57875B1 (https=) |
| SG (2) | SG11201501963RA (https=) |
| SI (1) | SI2900269T1 (https=) |
| WO (1) | WO2014048881A1 (https=) |
| ZA (1) | ZA201502840B (https=) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN104364239B (zh) | 2012-06-13 | 2017-08-25 | 霍夫曼-拉罗奇有限公司 | 二氮杂螺环烷烃和氮杂螺环烷烃 |
| MX368615B (es) | 2012-09-25 | 2019-10-09 | Hoffmann La Roche | Derivados bicíclicos como inhibidores de la autotaxina (atx) que son inhibidores de la producción de ácido lisofosfatídico (lpa) y el uso de los mismos. |
| AR095079A1 (es) | 2013-03-12 | 2015-09-16 | Hoffmann La Roche | Derivados de octahidro-pirrolo[3,4-c]-pirrol y piridina-fenilo |
| DK3074400T3 (en) | 2013-11-26 | 2018-01-15 | Hoffmann La Roche | Octahydro-cyclobuta [1,2-c; 3,4-c '] dipyrrole derivatives as autotaxin inhibitors |
| EA032357B1 (ru) | 2014-03-26 | 2019-05-31 | Ф. Хоффманн-Ля Рош Аг | Конденсированные [1,4]диазепиновые соединения в качестве ингибиторов продукции аутотаксина (atx) и лизофосфатидиловой кислоты (lpa) |
| CA2937616A1 (en) | 2014-03-26 | 2015-10-01 | F. Hoffmann-La Roche Ag | Bicyclic compounds as autotaxin (atx) and lysophosphatidic acid (lpa) production inhibitors |
| CN104829523B (zh) * | 2014-04-30 | 2017-10-31 | 药源药物化学（上海）有限公司 | 瑞戈非尼盐及其晶型、制备方法 |
| MA41898A (fr) | 2015-04-10 | 2018-02-13 | Hoffmann La Roche | Dérivés de quinazolinone bicyclique |
| CA2992889A1 (en) | 2015-09-04 | 2017-03-09 | F. Hoffmann-La Roche Ag | Phenoxymethyl derivatives |
| CN105267167A (zh) * | 2015-09-11 | 2016-01-27 | 江苏嘉逸医药有限公司 | 一种瑞戈非尼口服固体药物组合物的制备方法 |
| WO2017050732A1 (en) | 2015-09-24 | 2017-03-30 | F. Hoffmann-La Roche Ag | Bicyclic compounds as atx inhibitors |
| JP6876685B2 (ja) | 2015-09-24 | 2021-05-26 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ａｔｘ阻害剤としての二環式化合物 |
| BR112017026682A2 (pt) | 2015-09-24 | 2018-08-14 | Hoffmann La Roche | novos compostos bicíclicos como inibidores de dupla ação de atx/ca |
| AU2016328436B2 (en) | 2015-09-24 | 2020-05-14 | F. Hoffmann-La Roche Ag | New bicyclic compounds as dual ATX/CA inhibitors |
| PL3474858T3 (pl) * | 2016-06-28 | 2022-01-17 | Asamedic As | Dwuskładnikowa kompozycja zawierająca kwas acetylosalicylowy |
| RU2019132254A (ru) | 2017-03-16 | 2021-04-16 | Ф. Хоффманн-Ля Рош Аг | Гетероциклические соединения, пригодные в качестве дуальных ингибиторов atx/ca |
| JP7090099B2 (ja) | 2017-03-16 | 2022-06-23 | エフ．ホフマン－ラ ロシュ アーゲー | Ａｔｘインヒビターとしての新規二環式化合物 |
| CA3244313A1 (en) | 2017-06-02 | 2025-06-13 | Bayer Healthcare Llc | Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer |
| EP3501522A1 (en) | 2017-12-22 | 2019-06-26 | Asamedic AS | Compositions comprising acetylsalicylic acid and a phosphate salt |
| EP3501523A1 (en) | 2017-12-22 | 2019-06-26 | Asamedic AS | Two-component compositions comprising acetyl salicylic acid and a carbonate salt |
| KR20210156389A (ko) | 2020-06-17 | 2021-12-27 | 재단법인대구경북과학기술원 | 레고라페닙을 유효성분으로 포함하는 염증질환의 예방 또는 치료용 약학적 조성물 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2373940A1 (en) * | 1999-07-02 | 2001-01-11 | Hisamitsu Pharmaceutical Co., Inc. | Medicinal compositions for treating colorectal cancer |
| US20040121004A1 (en) * | 2002-12-20 | 2004-06-24 | Rajneesh Taneja | Dosage forms containing a PPI, NSAID, and buffer |
| EP1663978B1 (en) * | 2003-07-23 | 2007-11-28 | Bayer Pharmaceuticals Corporation | Fluoro substituted omega-carboxyaryl diphenyl urea for the treatment and prevention of diseases and conditions |
| EP1948144A2 (en) * | 2005-11-10 | 2008-07-30 | Bayer HealthCare AG | Diaryl urea for treating diabetic neuropathy |
| AR062927A1 (es) | 2006-10-11 | 2008-12-17 | Bayer Healthcare Ag | 4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada |
| GB201002530D0 (en) * | 2010-02-15 | 2010-03-31 | Univ Wolverhampton The | Di-aspirin derivatives |
| AR081060A1 (es) | 2010-04-15 | 2012-06-06 | Bayer Schering Pharma Ag | Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida |
-
2013
- 2013-09-23 EP EP13770659.4A patent/EP2900269B1/en active Active
- 2013-09-23 LT LTEP13770659.4T patent/LT2900269T/lt unknown
- 2013-09-23 BR BR112015006686-0A patent/BR112015006686B1/pt active IP Right Grant
- 2013-09-23 KR KR1020157010519A patent/KR102210575B1/ko active Active
- 2013-09-23 WO PCT/EP2013/069735 patent/WO2014048881A1/en not_active Ceased
- 2013-09-23 CN CN201380050150.7A patent/CN104994876A/zh active Pending
- 2013-09-23 MX MX2015003728A patent/MX357035B/es active IP Right Grant
- 2013-09-23 SG SG11201501963RA patent/SG11201501963RA/en unknown
- 2013-09-23 US US14/431,119 patent/US10898500B2/en active Active
- 2013-09-23 EA EA201500365A patent/EA032023B1/ru not_active IP Right Cessation
- 2013-09-23 SG SG10201702356VA patent/SG10201702356VA/en unknown
- 2013-09-23 JP JP2015532437A patent/JP6294888B2/ja active Active
- 2013-09-23 PL PL13770659T patent/PL2900269T3/pl unknown
- 2013-09-23 HU HUE13770659A patent/HUE039878T2/hu unknown
- 2013-09-23 ES ES13770659.4T patent/ES2687985T3/es active Active
- 2013-09-23 MY MYPI2015700911A patent/MY183969A/en unknown
- 2013-09-23 HK HK16102326.3A patent/HK1214169A1/zh unknown
- 2013-09-23 AU AU2013322854A patent/AU2013322854B2/en active Active
- 2013-09-23 PT PT13770659T patent/PT2900269T/pt unknown
- 2013-09-23 CA CA2885688A patent/CA2885688C/en active Active
- 2013-09-23 NZ NZ705860A patent/NZ705860A/en unknown
- 2013-09-23 DK DK13770659.4T patent/DK2900269T3/en active
- 2013-09-23 HR HRP20181462TT patent/HRP20181462T1/hr unknown
- 2013-09-23 RS RS20181015A patent/RS57875B1/sr unknown
- 2013-09-23 SI SI201331181T patent/SI2900269T1/sl unknown
-
2015
- 2015-03-12 IL IL237690A patent/IL237690B/en active IP Right Grant
- 2015-03-17 PH PH12015500587A patent/PH12015500587A1/en unknown
- 2015-03-24 CL CL2015000744A patent/CL2015000744A1/es unknown
- 2015-04-24 ZA ZA2015/02840A patent/ZA201502840B/en unknown
-
2018
- 2018-09-20 CY CY181100976T patent/CY1120939T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6294888B2 (ja) | 癌を治療するためのレゴラフェニブおよびアセチルサリチル酸の組み合わせ | |
| JP7806119B2 (ja) | 癌治療のためのレゴラフェニブとｐｄ－１／ｐｄ－ｌ１（２）阻害剤の併用 | |
| RU2774838C2 (ru) | Комбинация регорафениба и ингибиторов pd-1/pd-l1(2) для лечения рака | |
| HK40015063A (en) | Combination of regorafenib and pd-1/pd-l1(2) inhibitors for treating cancer | |
| HK40109111A (zh) | 用於治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品 | |
| HK40105741A (zh) | 用於治疗癌症的瑞格菲尼和pd-1/pd-l1(2)抑制剂的组合产品 |